Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-88.74	-78.06	-68.26	-43.59	-21.44
Depreciation & Amortization	5.48	5.41	4.21	1.73	0.39
Stock-Based Compensation	12.57	16.2	6.92	1.96	0.38
Other Adjustments	9.73	7.04	-7.85	0.14	-1.32
Change in Receivables	-0.37	1.19	-2.45	-	-
Changes in Accounts Payable	-1.86	-1.11	-0.08	0.72	0.7
Changes in Accrued Expenses	1.23	-0.89	1.63	4.53	1.85
Changes in Income Taxes Payable	-	-3.27	1.73	1.54	-
Changes in Unearned Revenue	-26.43	-46.8	-30.3	65.66	44.23
Changes in Other Operating Activities	-3.87	-8.79	3.04	-2.96	-0.52
Operating Cash Flow	-91.62	-109.07	-91.41	29.72	24.26
Operating Cash Flow Growth	-	-	-	22.54%	-
Capital Expenditures	-0.82	-3.11	-9.81	-13.98	-2.9
Sale of Property, Plant & Equipment	0.02	-	-	-	-
Purchases of Investments	-59.2	-306.42	-208.1	-214.85	-71.41
Proceeds from Sale of Investments	159.69	221.38	263.64	106.63	-
Investing Cash Flow	99.71	-88.16	45.73	-122.2	-74.32
Issuance of Common Stock	-0.19	84.01	-	-	-
Net Common Stock Issued (Repurchased)	-0.19	84.01	-	-	-
Issuance of Preferred Stock	-	-	4.3	239.59	9.95
Net Preferred Stock Issued (Repurchased)	-	-	4.3	239.59	9.95
Other Financing Activities	-0.54	-	-3.28	-	29.97
Financing Cash Flow	-0.68	84.01	1.01	239.59	39.92
Net Cash Flow	7.66	-113.22	-44.66	147.12	-10.14
Free Cash Flow	-92.45	-112.19	-101.22	15.75	21.35
Free Cash Flow Growth	-	-	-	-26.26%	-
FCF Margin	-299.05%	-214.53%	-226.17%	91.55%	8787.65%
Free Cash Flow Per Share	-2.48	-3.40	-29.73	4.63	-
Levered Free Cash Flow	-115.02	-136.63	-97.84	13.65	22.3
Unlevered Free Cash Flow	-117.22	-141.61	-118.54	9.81	19.79

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q